Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Actavis Pharma | 4,446.1 | 3,367.2 | 2,338.4 | | | | | |
| Anda Distribution | 986.4 | 776.2 | 830.7 | | | | | |
| Actavis Specialty Brands | 482.4 | 441.0 | 397.8 | | | | | |
| Total revenues [+] | 5,914.9 | 4,584.4 | 3,566.9 | 2,793.0 | 2,535.5 | 2,496.7 | 1,979.2 | 1,646.2 |
| Products | | | | | 2,535.5 | | | |
| Revenue growth [+] | 29.0% | 28.5% | 27.7% | 10.2% | 1.6% | 26.1% | 20.2% | 0.3% |
| Actavis Pharma | 32.0% | 44.0% | | | | | | |
| Anda Distribution | 27.1% | -6.6% | | | | | | |
| Actavis Specialty Brands | 9.4% | 10.9% | | | | | | |
| Cost of goods sold | 3,390.4 | 2,564.9 | 1,998.5 | 1,596.8 | 1,502.8 | 1,504.8 | 1,233.5 | 852.4 |
| Gross profit | 2,524.5 | 2,019.5 | 1,568.4 | 1,196.2 | 1,032.7 | 991.9 | 745.8 | 793.8 |
| Gross margin | 42.7% | 44.1% | 44.0% | 42.8% | 40.7% | 39.7% | 37.7% | 48.2% |
| Selling, general and administrative [+] | 1,171.3 | 754.9 | 756.1 | 520.2 | 423.4 | 421.1 | 305.1 | 261.0 |
| Sales and marketing | 546.5 | 401.8 | 320.0 | 263.1 | 232.9 | 215.4 | 173.5 | 162.3 |
| General and administrative | 624.8 | 353.1 | 436.1 | 257.1 | 190.5 | 205.7 | 131.5 | 98.7 |
| Research and development | 401.8 | 295.4 | 296.1 | 197.3 | 170.1 | 144.8 | 131.0 | 125.3 |
| Equity in earnings | | | | | | | | |
| Other operating expenses | 630.6 | 433.0 | 210.8 | 94.8 | 81.0 | 170.3 | 234.0 | 189.0 |
| EBITDA [+] | 899.4 | 984.1 | 587.3 | 572.9 | 528.9 | 685.7 | 457.8 | 589.2 |
| EBITDA growth | -8.6% | 67.6% | 2.5% | 8.3% | -22.9% | 49.8% | -22.3% | 20.0% |
| EBITDA margin | 15.2% | 21.5% | 16.5% | 20.5% | 20.9% | 27.5% | 23.1% | 35.8% |
| Depreciation | 97.5 | 93.6 | 101.9 | 96.4 | 90.0 | 253.6 | 218.3 | 206.7 |
| EBITA | 801.9 | 890.5 | 485.4 | 476.5 | 438.9 | 432.1 | 239.4 | 382.5 |
| EBITA margin | 13.6% | 19.4% | 13.6% | 17.1% | 17.3% | 17.3% | 12.1% | 23.2% |
| Amortization of intangibles | 481.1 | 354.3 | 180.0 | 92.6 | 80.7 | 176.4 | 163.7 | 163.9 |
| EBIT [+] | 320.8 | 536.2 | 305.4 | 383.9 | 358.2 | 255.7 | 75.7 | 218.5 |
| EBIT growth | -40.2% | 75.6% | -20.4% | 7.2% | 40.1% | 237.8% | -65.4% | -30.0% |
| EBIT margin | 5.4% | 11.7% | 8.6% | 13.7% | 14.1% | 10.2% | 3.8% | 13.3% |
| Non-recurring items [+] | | | | | | | 497.8 | |
| In-process research & development | | | | | | | 497.8 | |
| Interest expense, net [+] | 114.2 | 79.7 | 82.5 | 29.2 | 19.2 | 35.6 | -6.3 | -4.8 |
| Interest expense | 116.7 | 81.8 | 84.1 | 34.2 | 28.2 | 44.5 | 22.1 | 14.5 |
| Interest income | 2.5 | 2.1 | 1.6 | 5.0 | 9.0 | 8.9 | 28.4 | 19.3 |
| Other income (expense), net [+] | 38.5 | -0.5 | 27.7 | 7.9 | 19.3 | 4.1 | 4.8 | -3.4 |
| Gain (loss) on investments | 28.8 | 0.8 | 25.6 | -1.1 | 9.6 | | | |
| Gain (loss) on debt retirement | | | | | | -5.6 | -0.5 | |
| Other | 38.5 | -0.5 | 27.7 | 7.9 | 19.3 | -9.7 | -5.3 | 3.4 |
| Pre-tax income | 245.1 | 456.0 | 250.6 | 362.6 | 358.3 | 224.2 | -410.9 | 219.9 |
| Income taxes | 146.8 | 196.9 | 67.3 | 140.6 | 119.9 | 83.2 | 34.1 | 81.4 |
| Tax rate | 59.9% | 43.2% | 26.9% | 38.8% | 33.5% | 37.1% | | 37.0% |
| Minority interest | -1.0 | 1.8 | 1.1 | | | | | |
| Net income | 99.3 | 257.3 | 182.2 | 222.0 | 238.4 | 141.0 | -445.0 | 138.6 |
| Net margin | 1.7% | 5.6% | 5.1% | 7.9% | 9.4% | 5.6% | -22.5% | 8.4% |
| |
| Basic EPS [+] | $0.79 | $2.07 | $1.49 | $2.11 | $2.32 | $1.38 | ($4.37) | $1.32 |
| Growth | -61.8% | 38.8% | -29.6% | -8.8% | 68.3% | -131.5% | -431.2% | -3.9% |
| Diluted EPS [+] | $0.77 | $2.03 | $1.47 | $1.91 | $2.03 | $1.21 | ($4.37) | $1.15 |
| Growth | -62.0% | 38.7% | -23.1% | -5.8% | 68.1% | -127.6% | -478.8% | -4.0% |
| |
| Shares outstanding (basic) [+] | 125.8 | 124.5 | 122.4 | 105.0 | 102.8 | 102.3 | 101.8 | 104.9 |
| Growth | 1.0% | 1.7% | 16.6% | 2.1% | 0.5% | 0.5% | -3.0% | -3.9% |
| Shares outstanding (diluted) [+] | 128.4 | 126.5 | 124.2 | 116.4 | 117.7 | 117.0 | 101.8 | 120.0 |
| Growth | 1.5% | 1.9% | 6.7% | -1.1% | 0.6% | 15.0% | -15.2% | -3.8% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|